WC
TRVI icon

Wexford Capital’s Trevi Therapeutics TRVI Stock Holding History

Wexford Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Hold
90,752
– – 0.22% 46
2026
Q1 		$1.08M Buy
90,752
+8,718
+11% +$97.6K 0.16% 58
2025
Q4 		$1.03M Buy
+82,034
New +$948K 0.2% 76
2025
Q2 		– Sell
-40,000
Closed -$252K – 322
2025
Q1 		$252K Buy
+40,000
New +$191K 0.07% 173

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Wexford Capital's TRVI Position: Q2 2026 in Review

Wexford Capital held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 90,752 shares worth $1.69M. The position accounts for 0.22% of the portfolio, ranked #46.

Wexford Capital first reported a position in TRVI in Q1 2025 and has held it in 4 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Wexford Capital held 90,752 shares of Trevi Therapeutics worth $1.69M as of Q2 2026.
  • Wexford Capital left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up 0.22% of Wexford Capital's portfolio in Q2 2026, its #46 holding.
  • Wexford Capital first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.